Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 165.49M P/E - EPS this Y 19.10% Ern Qtrly Grth -
Income -64.47M Forward P/E -2.78 EPS next Y 16.20% 50D Avg Chg 1.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 10.00%
Dividend N/A Price/Book 1.31 EPS next 5Y - 52W High Chg -61.00%
Recommedations 1.60 Quick Ratio 7.04 Shares Outstanding 15.06M 52W Low Chg 289.00%
Insider Own 6.15% ROA -60.09% Shares Float 10.22M Beta 2.18
Inst Own 55.97% ROE -112.67% Shares Shorted/Prior 327.30K/282.04K Price 1.50
Gross Margin - Profit Margin - Avg. Volume 326,524 Target Price 67.50
Oper. Margin - Earnings Date May 10 Volume 207,611 Change -1.96%
About Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

Jasper Therapeutics, Inc. News
03/21/24 Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
03/19/24 Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
03/15/24 New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
03/04/24 Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
02/26/24 Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference
02/23/24 Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
02/07/24 Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference
02/06/24 Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock
02/05/24 Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
02/02/24 Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/05/24 Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones
01/02/24 Jasper Therapeutics, Inc. Announces Reverse Stock Split
12/10/23 Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023
11/30/23 Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria
11/09/23 Jasper Therapeutics Inc (JSPR) Reports Q3 2023 Financial Results and Business Progress
11/09/23 Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
11/08/23 Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences
11/02/23 Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023
11/01/23 Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors
10/09/23 Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023
JSPR Chatroom

User Image cheating_stock_investor Posted - 7 hours ago

$JSPR the cat was let out of the bag too soon. More funds buying this up, once trials come out later this year and are positive the stock will go over 100 and new pt will be 120.

User Image erevnon Posted - 12 hours ago

RBC Capital initiates coverage on Jasper Therapeutics $JSPR at Outperform rating and a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

User Image GuyFawkes_EOD Posted - 6 days ago

$MLGO micro float post rs $LLAP $DTIL $JSPR

User Image Stock_Titan Posted - 1 week ago

$JSPR Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference https://www.stocktitan.net/news/JSPR/jasper-therapeutics-to-participate-in-the-h-c-wainwright-2nd-annual-ogipun3zpvia.html

User Image THEINVESTMENTSWAMI Posted - 1 week ago

$JSPR ๐Ÿ‘๏ธJSPR๐Ÿ‘๏ธ- STILL WATCHING๐Ÿ‘๏ธ๐Ÿ‘๏ธ๐Ÿ‘๏ธ๐Ÿง ๐Ÿ‘ณโ€โ™‚๏ธ๐Ÿง 

User Image cheating_stock_investor Posted - 1 week ago

@ClipSave people want to hit that home run even if it means striking out. I rather get a .400 batting average with 5 home runs for the season than bat .175 with 30 home runs. The fact the insiders treat this company the way they do tells you something. Amy is probably saved up enough for retiring so she can care less about where this goes. I would want someone to put at least even 50k down. Look at $jspr insiders been buying even though the company hasnt made a dime. It's all based on insider confidence. Btw, having experience being a majority shareholder and controlling some board seats what i will tell you is a director who is unloading shares the extent of paddy should not even be on board. Especially when he's selling in open market on a downward trajectory, he would sell blocks to interested parties who will take his share if he cared and believed this was going in an upward direction. If he was selling to diversify he wouldnt sell the way he is

User Image cheating_stock_investor Posted - 1 week ago

$JSPR rug pull or magic carpet ride

User Image GuyFawkes_EOD Posted - 1 week ago

$JSPR woohoo 52 week high, keep on climbing ๐Ÿง—

User Image TheTradeXchange Posted - 1 week ago

$JSPR - Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

User Image Stock_Titan Posted - 1 week ago

$JSPR Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria https://www.stocktitan.net/news/JSPR/jasper-therapeutics-announces-first-patient-dosed-in-phase-1b-2a-g11dg5xfrqf2.html

User Image Stock_Titan Posted - 1 week ago

$JSPR New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia https://www.stocktitan.net/news/JSPR/new-positive-data-presented-on-briquilimab-conditioning-in-patients-fgk8u94hwq20.html

User Image cheating_stock_investor Posted - 1 week ago

$JSPR the only reason this dipped last year was to tax loss harvesting. Short term investors dont know what that is.

User Image GuyFawkes_EOD Posted - 2 weeks ago

$JSPR check out the three month chart

User Image GuyFawkes_EOD Posted - 2 weeks ago

$JSPR tough day but still bullish af

User Image Miami_Cash Posted - 2 weeks ago

$JSPR itโ€™s over bought will dip back down to itโ€™s real value

User Image Miami_Cash Posted - 2 weeks ago

$JSPR this company has a history of going back down to $4 dollars , itโ€™s a goon bs company . Goodluck

User Image Miami_Cash Posted - 2 weeks ago

$JSPR rug pull inbound

User Image BenKaitz Posted - 2 weeks ago

$JSPR 480% return in three months. Good luck to all. Keeping 20% of my shares.

User Image insiderbuyingselling Posted - 2 weeks ago

$JSPR new insider selling: 900 shares. http://insiderbuyingselling.com/?t=JSPR

User Image Trubach Posted - 2 weeks ago

$NRXP Look at $JSPR , it did 1:10 RS in January, stock was at $7 after RS, now its trading at $26. Its all about value.

User Image Stocks4thought Posted - 2 weeks ago

$JSPR Ever since the Wall Street bet bonanza $AMC thing. everything you wanted to know about sex (STOCKS) , or knew is out the window. CONTRA - stock split was viewed with disdain- now its sexy and can be manipulated with huge rewards. Wasn't this below a dollar. .70 cents ?

User Image the_ipodude Posted - 3 weeks ago

$JSPR is tht like a BS $80 outperform target by these goons

User Image GuyFawkes_EOD Posted - 3 weeks ago

$JSPR

User Image GuyFawkes_EOD Posted - 3 weeks ago

$CYCC $JSPR $LLAP

User Image erevnon Posted - 3 weeks ago

Oppenheimer maintains Jasper Therapeutics $JSPR at Outperform and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

User Image cheating_stock_investor Posted - 3 weeks ago

$JSPR 80 price target from analyst i still wont sell if it gets there. This is a keeper stock to triple digits.

User Image GuyFawkes_EOD Posted - 3 weeks ago

$JSPR fully funded until late 2025, no fear of offerings

User Image GuyFawkes_EOD Posted - 3 weeks ago

$JSPR nice close

User Image jacksparo Posted - 3 weeks ago

$JSPR From My Previous Magic Micro cap! New list with new 5 tickers has been released last night! Those are real money monsters ๐Ÿ’ฒ๐Ÿ’ฒ๐Ÿ’ฒ๐Ÿš€๐Ÿš€๐Ÿš€!

User Image Darkgold Posted - 3 weeks ago

$CYCC $LLAP $JSPR +200% at least would be deserved

Analyst Ratings
RBC Capital Outperform Mar 28, 24
TD Cowen Outperform Mar 18, 24
Oppenheimer Outperform Mar 7, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
WIGGANS THOMAS G Director Director Nov 16 Buy 0.61 30,000 18,300 30,000 11/20/23
Lis William Director Director Oct 13 Sell 0.8508 7,965 6,777 53,521 10/13/23
Mahal Jeetinder Singh See Remarks See Remarks Jun 13 Sell 1.66 9,000 14,940 287,223 06/13/23
Mahal Jeetinder Singh See Remarks See Remarks Jun 13 Option 0.71 9,000 6,390 296,223 06/13/23
Qiming U.S. Healthcare Fund II... 10% Owner 10% Owner Jan 27 Buy 1.50 2,666,666 3,999,999 8,519,648 04/11/23
Carlyle Group Inc. 10% Owner 10% Owner Jan 27 Buy 1.50 3,133,333 4,700,000 8,761,891 01/31/23
- - - Feb 22 Sell 10.48 12,810 134,249 1,050,002 02/22/21
- - - Dec 31 Sell 10.25 93 953 1,073,125 12/31/20
- - - Dec 28 Sell 10.18 20,000 203,600 1,073,218 12/28/20
- - - Dec 15 Sell 10.08 20,000 201,600 1,093,218 12/15/20
- - - Dec 09 Sell 10.39 12 125 1,113,218 12/09/20
- - - Dec 09 Sell 10.39 12 125 1,113,218 12/09/20
- - - Dec 09 Sell 10.39 12 125 1,113,218 12/09/20
- - - Sep 18 Sell 10 1,020 10,200 1,114,230 09/18/20